Kaken Pharmaceutical Co (TSE:4521) Total Liabilities : 円28,202 Mil (As of Dec. 2023)

View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co Total Liabilities?

Kaken Pharmaceutical Co's Total Liabilities for the quarter that ended in Dec. 2023 was 円28,202 Mil.

Kaken Pharmaceutical Co's quarterly Total Liabilities increased from Jun. 2023 (円29,320.00 Mil) to Sep. 2023 (円30,923.00 Mil) but then declined from Sep. 2023 (円30,923.00 Mil) to Dec. 2023 (円28,202.00 Mil).

Kaken Pharmaceutical Co's annual Total Liabilities increased from Mar. 2022 (円26,858.00 Mil) to Mar. 2023 (円29,493.00 Mil) but then declined from Mar. 2023 (円29,493.00 Mil) to Mar. 2024 (円27,868.00 Mil).

Kaken Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Kaken Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Total Liabilities Chart

Kaken Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

29,408.00

27,076.00

26,858.00

29,493.00

27,868.00

Kaken Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															29,493.00	29,320.00	30,923.00	28,202.00	27,868.00

Kaken Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Kaken Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	19024	+	(0	+	2314
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	6530)
	=	27,868

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	171623	-	143755
	=	27,868

Kaken Pharmaceutical Co's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	19550	+	(0	+	2220
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	6432)
	=	28,202

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	168337	-	140135
	=	28,202

Kaken Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kaken Pharmaceutical Co (TSE:4521) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

KKPCF:USA

Address

28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650

Website

http://www.kaken.co.jp

Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines